Updated ACR guidelines for JIA treatment
The American College of Rheumatology (ACR) published 2 updated guidelines for juvenile idiopathic arthritis (JIA) treatment and management.1,2 The first guideline discusses nonpharmacologic therapies, medication monitoring, immunizations, and imaging, regardless of the JIA phenotype.1 The second guideline mainly provides updates for pharmacologic management of JIA, precisely focusing on the treatment of temporomandibular joint (TMJ) arthritis, oligoarthritis and systemic JIA, regardless of the macrophage activation syndrome (MAS).2